Clinical Trial Update: A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Naïve Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 study evaluating LY01008 in combination with Bevacizumab, Paclitaxel, and Carboplatin for treatment-naïve metastatic or recurrent non-small cell lung ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)
• LY01008
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Luye Pharma Group Ltd. | Conditions: Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic | Phase 3 | Status: UNKNOWN